Strong BUY BCG cmp 17.45, target 22.50/26.50 in few days Brightcom Group Ltd(BCG) offers digital marketing solutions to businesses, agencies and online publishers worldwide.
Services Provided:
The Company is divided into three major divisions:
a. Ad-Tech and Digital Marketing:
The services include Video Advertising, Display Ads Marketing, Performance-based Marketing, Search Marketing, Email Marketing and Lead Generation, Afliate Marketing, Social Marketing, Mobile Marketing, Niche Campaigns, Digital Trafc Management, Ad Serving
b. Software services:
The Company’s software services include developing customized technology platforms to solve specific needs of clients primarily around digital media and other related offerings
c. Future technologies:
The company’s future technologies division consists primarily of the Company’s LIFE product and developments in artificial intelligence, machine learning and Digital Out of Home(DOOH) advertising.
Revenue Breakup - Q1FY24
Advertising Revenue : 94%
Software Revenue : 5%
Other Revenue : 1%
Interim Order By SEBI
An Interim order was passed by SEBI on 22.08.23 related to concerns regarding preferential allotment made by the company in FY20 & FY21. They suspected that money raised were given as loans and advances to its subsidiaries. It was also alleged that proper disclosures were not made in the Annual report and also disclosures related to preferential utilisation were not made. Post this the entire management of Brightcom has stepped down.
Forensic Audit:
SEBI ordered Forensic Audit of company on 16/09/2021 and Deloitte Touche Tohmatsu India LLP were appointed as forensic auditor w.r.t the financial statements from FY 2014-15 to FY 2019-20. The said Forensic Audit is under progress and the final outcome of the investigation is yet to come by the time of certification
Market Cap - ₹ 3,513 Cr.
Book Value - ₹ 34.7
Price to book value - 0.51
Debt - ₹ 0.00 Cr.
EPS - ₹ 7.01
ROCE - 30.9 %
Stock P/E - 2.51
Industry PE - 34.1
Currently the stock is terribly undervalued and we feel all the negatives is deeply discounted and technically it completely bottomed out at this valuation. We have recently the strong buying appearing and there is a good buying pattern emerging. So we strongly suggest a buy in BCG shares at 17.45 and buy till 18.5 for a target of 22.50 and 26.50. Valuation wise even at 26.5 its a buy but technically these are the resistance levels appearing. Stop loss 16
Pennystocks
ACB a Cannabis Penny Stock LONGACB is moving of late due to the legalization of marijuana in Germany as well as the election
referendum in Florida in November. It is the best capitalized of the peer penny stocks in
this sector. Today from the low at the opening bell to the high before the NY lunch hour, ACB
moved about 30%. There was both a long and short trade here. The options moved
multiples. National MJ Day is April 20th. I expect these stocks to keep moving at least
until then. ACB is getting support from the mean anchored VWAP line and is able to run
with its bullish momentum to the second upper VWAP line before the shorts take positions
and longs realize profits. Since ACB is now situated at the mean VWAP, it is set up for
a long entry now.
ESPR a penny and medtech stock LONGESPR on the 120-minute chart is surging with momentum from an FDA approval for a new
cholestrol and lipid medication which will be an alternative to the at statin class which has
side effects and can cause diabetes. I am familar with a few of the professionals on the
science advisory board they are researchers and academics of the highest claiber. The chart
shows price testing and getting support from the mean VWAP and a little bit of resistance
from the first upper VWAP line. I have added to my existing position at the consolidation at
VWAP. I am well informed on ESPR market prospects; this could be disruptive.
The dual time frame RSI of Chris Moody has curled up and validates the idea. My interim
target is the double top of this past winter. I do expect increasing volume in time with the
price action that follows.
Disclaimer This a hot penny stock highly volatile - you could lose on this trade. Do not trade
with money you cannot afford to lose. You must manage the trade well to realize profit.
There are options if the put to call ratio is rising big money is pushing a reversal
CZOO moves up on the pre-earnings interest LONGCZOO shown on a reliable daily chart had an earnings report beating the estimates back in
November whereprice action trended up then down in January followed by sideway action
then finally a break out through VWAP band lines and the entirety of the high volume area of
the profile. Ahead above is a volume void where price moved quickly coming down..
On the retrace, price can move through the void just as easily.
The indicators show the volume pump and corresponding Price Volume Trend going exponential
My first target is 23 about 90% upside - it is the line between the lows of the bottom wicks of
Doji candles on 11/17 and 12/18/23. The stop loss is 12.6 just below the upper
boundary of the high volume area. Once the price gets over 17, the stop loss will be
converted to a trailing $2.00 stop loss and the risk free trade will continue higher.
At the first target 50% will be realized and at the second another 25% while the remaining will
be left to see if any momentum remains. The final target is 43 being the high pivots of early
December 23 and the consolidation high volume area of October 23. the rest will look for the
momentum fade while the stop loss is changed to trailing $1.00.
This is potentially a 3-4X profit trade using alerts / notifications/ limits and stops.
There will be very little screen time or effort in the management.
VOR - a b iotechnology penny stock LONGVOR is a on daily chart. It is a biotechnology startup which is burning cash. As a resut this is
a speculative long trade for this company with products to treat leukemia ( blood cancer).
Price has crossed over the POC line of the volume profile and also completed an
anchored mean VWAP cross over. The Price Momentum Oscillator is reversing and buying
volume has increased since the earnings report showed less of a loss than forecasted.
I see 30% upside to the high pivot in mid-January. In conjunction with stop- loss set at the mean
anchored VWAP this is a R to r of about 3.
NKLA can this EV penny stock stop the cash burn/ News LONGNKLA on the 120 minute chart has been in a falling wedge pattern and had the news of
hydrogen stations ready to go in the all important California market and now printed a
countertrend breakout over the wedge. Can Nikola stop the cash burn? Can it prevent further
shareholder dilution? Is the board protecting the interests of shareholders ? While this gets
figured out can price rise to the anchored mean VWAP and put in a 10% jump in the short term?
I intend to find out.
OCGN pumps on dismissal of investor lawsuit LONGOCGN has been a great swing trade after buying bad news. The good news has replaced the
bad. Earnings are in three days. Price well below ATH. November earnings were a beat
meaning this risky Med Tech penny stock had a lower cash burn than projected. Now
legal costs will disappear. Going long with a decent position expecting a better earnings.
In law, the Latin phrase res ipsa loquitur is sometimes used. Here it aptly applies to
Ocugen.
WULF a high volatility AI penny stock LONGWULF on a daily chart has room to run to a end of the year pivot high and the ATH of July 23
The relative trend indicator shows it rising out of of the chop zone and the RSI shows lines
popping over 50. My targets are 3.1 and 3.8 the red lines from the tweezer tops. PRice has
crossed the mean VWAP a bullish momentum stimulus. It is a cheap but risk way to take
an entry in a swing trade long on WULF and the AI subsector of technology. Upside is 50-75%
overall with a stop loss of 10% raised to break =even once price is 10% above entry and changed
to 5% trailing once price is over 25% above the entry. This is a low time and effort type of trade
meant to extract high profit relative to time/effort also with the use of alerts and notifications
to manage the trade.
(Buy Alert) Stock: LPSN - Risk/Reward 12 - 1st TP 28%, 2nd 74%(Buy Alert) Stock: NASDAQ:LPSN - Risk/Reward 12 - 1st TP 28%, 2nd 74%
Buy Limit: $0.97
1st Take Profit Limit: $1.22
1st Take Profit Limit: $1.68
Stop Loss: $0.90
Market capitalization
89.43 MUSD
Free Float shares
66.43 M
Debt: $591M
Cash and Equivalent: $212M
VINC update to previous ideas LONGVINC on the 15 minute chart was sideways at the top and put in a 20% short trade today which
was straightforward an easy. A 50% partial taken off at the mid-day counter trend then the
remainder of 50% off before the close. Idea is on the chart; see also the previous ideas.
Expecting a full reversal in the pre-market trading and a good intraday trade at least until
the NY lunch hour.
TSHA a medtech penny stock pumps on news and earnings LONGTSHA is a gene technology medical company which reported on its clinical trials for Rett
Syndrome which is a neurobehavioral disorder separate from others like autism or
schizophrenia. This could be a breakthrough medication for those who suffer from Rett.
TSHA102 could be heralded as a miracle treatment ( not a cure). Price had trended up
in February and then down in March and is now situated at the mean anchored VWAP.
Relative volumes are 5-10X the running mean. I am taking a sizeable position here based
also on my background as well as the forecasts of medical technology stocks as being hot right
now especially small caps. Risk is definitely on. TSHA has been selling off parts of its pipeline
to fortify its core. This tells me leadership is realistic and has a survival plan which is a big plus
in the world of young and small medical technology companies. The earnings report from
yesterday showed a big earnings beat and a transition from cash burning to positive earnings.
Part of this is from selling off part of its future. Nonetheless, that future may be very bright
with what remains. I believe that TSHA will consolidate and gain consensus as to fair value
but then resume bullish continuation. This may be a buy and hold until the next earnings while
watching for clinical trial news that will give a hint as to the growth path.
VINC Biotech Penny Stock Followup Swing TradesVINC was a penny stock and is now in the near penny category as this biotech stock has had
a great run in the past 10 days. On the 30 minute chart, 225 shares are bought at low prices
and 125 shares are sold for profit with 100 shares still running as the momentum slows.
Overall, the trades where profitable averaging 12% daily in an average trade of 4.5 days.
Time and effort in the trade were minimal as the price action was monitored by alerts
and notifications as to price to moving average and moving average to moving average crosses
as well as dips and peaks of RSI under 40 or over 70 to notify for potential buys or sells
in this zig-zag strategy which intended to optimize profit and minimize time and effort
in trading.
Now what?Seems like 3.5 is a string demand area that pushes the price very hard to the upside. The last time was in Jan 2020. I don't think is going to explode above 30 but the next resistance is at 10. This is a high volatile stock, I bought calls exp 04/19 strike 5.5. If this breaks out will be massive.
BBAI - a penny stock in a hot sector LONGBBAI fell on an earnings miss on Thursday March 7th. The downtrend of 30% was basically a
slow flush. Penny stocks are volatile to begin with; this one is in the hottest of subsectors.
Price is in the hard oversold area just above the second lower VWAP line on this 15 minute
while the RSI lines are in the mid-30s showing the price weakness. A predictive forecasting
algo from Luxalgo suggests a bounce from the present price. I will take a long trade targeting
a return of 25% over the next week with three targets and partial closures of 25% , 50 and
25% respectively with the targets shown on the chart. The stop loss is 2.50 just below the
pivot low of 2.5. This trade idea demonstrates how penny stocks have great volatility and
how if entered well can result in 25% weekly which if compounded regularly can result
in rapid account balance growth overall. The trade is to be managed with partial closures
directed by alerts and notifications as well as a trailing stop loss of 5% once the price gain
has reached 10-15%. This minmizes effort and screen time so that they can be spread
across a wider variety of trades.
MVIS Microvision breaks higher from earnings LONGMVIS is a volatile penny stock with daily volumes in the 20JK range and a low float. Yesterday
was a decent earnings beat. MVIX was already trending up into the earnings and now may
sustain that trend up. Volatility and volume indicator support my supposition that the trend
is real. The target of the consolidation period of February 8-13's price level of 2.58 is
13 % upside. I espect this to be a long swing trade lasting a few days. Upon reaching the
target I will take half the position to realize that part of the profit and run the rest.
BLUE- a biotechnology earnings penny stock LONGBLUE a week ago had a bull run to gain 90% in 5 days and then reversed into a standard
Fibonacci retracement on the 30-minute chart, then in consolidation for a day or two getting
support from the mean anchored VWAP. The last trading day was a quick rise with momentum
in a bull flag. Earnings are coming. I will take another long trade on BLU into earnings. My
target is 1.90 about the high of the prior trend up and below the second VWAP line above
the mean. A tight stop loss at 1.53 ( below the flag's consolidation) will make it more likely the
trade will be a 20% winner. I have taken call options strikng $1.50 for March 15th for $20 each.
or a small loss of 2-3%
MYO can Myomo continue the push to the earnings report?MYO had impressive week gaining over 35%. It is a volatile penny biotechnology stock
with good earnings back in November new due for another report. On a 120 minute chart
with relative volatility and volume indicators and a volume profile added. The volume and
volativlty of this past week's move is obvious. Price gain has slowed on the approach to the
POC line of the volume profile which appears to be resistance. Price may break that resistance
but could get rejected there. I plan to buy MYO long on a break of resistance with
a buy stop set at 4.04 and a stop loss at 3.96. If MYO rises and gets over 4.04 the order should
fill and if it retests the POC line as support and the support fails, the stop will close the trade.
My expectation however is for the earnings run to take it to the level of the pivot high
in early January for a 25% gain.
EXFY a fintech penny stock at 5% of the ATH LONGEXFY recently had an earnings beat and has bullish momentum. While on a sixty minute chart it
may appear to be overextended, in the context of an all-time-high of about $50 perhaps it
has as much as 20X upside. EXFY rose from the earnings beat and then retraced and reversed the
retracement. I see it as a long wing trade perhaps until the approach to the next earnings.
The volume and volatility indicators suggest bullish momentum is strong and may continue.
LEXX a penny medical stock LONGLEXX on the daily chart is on a big bullrun breaking out of an ascending broadening triangle
or megaphone pattern demostrative of increasing volatility. Retlative volumes are 2X the
historical comparison. Price is now on the approach to the highs of 2023 but is only 15% of
the all high highs of 19 at the neckline of a head and shoulders back in 2018-2019, In short
it has a lot of upside if it can show earnings growth on higher revenues. For now targets are
4.15 the high of 2022 and 6.45 the high of 2021 marked on the chart in black horizontal
lines. LEXX is a money burning medical penny it is high risk like its peers. The reward
potential is as much as 7X and more realistically 2X in the intermediate term.
I will so long here with the risk in mind in the context of the reward potential.
FSR is driving to its earnings LONGFSR is shown here on a 30 minute chart on the move up in the approach to earnings on February
29th. For comparison purposes only TSLA is shown sideways with the purple line. FSR has
started a VWAP band breakout into the area of the mean anchored VWAP where it could pick up
institutionally based trader interest. The growing volumes of trading are obvious and lend
further support to taking a position. I will long long here with both shares and options
as a pre-earnings play. The call options for mid-March are $ 6.00 per contract.
MYO a Stock I randomly pulled up and conducted some R/AR/A = Research and Analysis
This stock just randomly chose to after looking at a few robotics stock. I went through a few stocks to show how I conduct my R/A and wanted to see if I could find some ideas and themes to trade. A stock that got selected was MYO. MYO is a company that sells robotic arms to people regain function in their arms and hands. Their product is called MyoPro. This stock might be able to push higher in the longer term (maybe in 2025). The technicals are not good on it. The fundamentals aren't also. And there is almost no sentiment on this stock because there is close to 0% PR on here, expect some articles talk about price movement. But, something that I saw that caught my eye is an individual in Australia used their product, was able to get their function back, and was able to benefit from the Nation Disability Insurance Scheme (NDIS) in Australia. Another that caught my eye is they are attempting to get their product approved for claims for Medicare Part B beneficiaries. If this is approved, the stock might be able to push above the $1 lvl and maybe push above the $2. So, this stock might have some promise. For now, I wouldn't get in because of the state of the economy, high inflation, and rates increasing. There are also the negatives aside from this stock almost collapsing, which is it's competitors and technologies such as Neuralink from Elon Musk.
I am not in this stock and highly likely I won't get in. This is just some research I have done and I am seeing where price is going to move and to see if I am correct.
Novavax- NVAX- Medical Technology Vaccine Focused LONGNVAX on the 15 minute chart has been compressing price action volatility into a symmetrical
triangle. It in now in a breakout of the triangle and in the process when from undervalued on
Monday to the upper trendline and then down to the support trendline and then up again.
It passed through the volume profile and its high volume area. In short, it has bullish
momentum capped off with a breakout from the high volume area into a bullflag to rest the
weekend. I am in this stock going and now is an opportunity to add to the position. If a trader
wants to know what I consider to be targets upside, let me know. Medical technology is
expected to be among the hottest of subsectors for 2024. NVAX has been beaten down. I
believe it has significant upside for the long term. in the short term, earnings are expected
on February 28th so this is a trade to consider on that run up. Call options for March 2 or March
16 can be considered.